<DOC>
	<DOC>NCT00779064</DOC>
	<brief_summary>This is a clinical study investigating pharmacokinetics, pharmacodynamic effects and safety of BAY 59-7939 in patients with atrial fibrillation (originally described in Japanese).</brief_summary>
	<brief_title>BAY59-7939, Japanese Phase II in Atrial FibrillationTrial Status</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>20 years or older Japanese male or female Non valvular atrial fibrillation documented by ECG Patients aged 60 years and older or with a risk of stroke Prior stroke and TIA Patients in whom anticoagulants are contraindicated</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Atrial Fibrillation</keyword>
</DOC>